2022-05-16T09:51:07-05:00 2021-12-31 872525370 CITRIN COOPERMAN ADVISORS LLC 50 ROCKEFELLER PLAZA NEW YORK NY 10020 990 2021-01-01 141935776 LUNG CANCER RESEARCH FOUNDATION LUNG 2125881580 501 SEVENTH AVE SUITE 401 NEW YORK NY 10018 DENNIS CHILLEMI EXECUTIVE DIRECTOR 2125881580 2022-05-09 1 DENNIS CHILLEMI 999009999 AMYN GILLANI P01522152 2126971000 2022-05-09 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z X DENNIS CHILLEMI 501 SEVENTH AVE SUITE 401 NEW YORK NY 10018 6403415 0 X WWW.LCRF.ORG X 2005 NY THE MISSION OF THE LUNG CANCER RESEARCH FOUNDATION IS TO IMPROVE LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. 15 15 19 10 0 0 5465693 6344359 0 0 1357 1402 -154610 -191509 5312440 6154252 1189629 1799919 0 0 2615442 2054786 127772 73650 622317 1095176 1412133 5028019 5340488 284421 813764 4581958 5738095 1887724 2230097 2694234 3507998 X THE MISSION OF THE LUNG CANCER RESEARCH FOUNDATION IS TO IMPROVE LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. 0 0 2633214 1799919 RESEARCH:DESPITE BEING THE LEADING CAUSE OF CANCER MORTALITY, LUNG CANCER RECEIVES FAR LESS RESEARCH FUNDING PER DEATH. LUNG CANCER RECEIVES $3,580 PER DEATH COMPARED TO BREAST CANCER AT $19,050, PROSTATE CANCER AT $8,116, AND PANCREATIC CANCER AT $4,796. THAT IS WHY FUNDING FROM NON-GOVERNMENTAL ORGANIZATIONS IS SO CRITICAL. THE LUNG CANCER RESEARCH FOUNDATION (LCRF) PLAYS A PIVOTAL ROLE IN THIS FUNDING LANDSCAPE, SUPPORTING EARLY-CAREER INVESTIGATORS WHO, IF NOT FOR OUR FUNDING, MAY NOT RECEIVE FUNDING AT ALL. SINCE 2005, THE LUNG CANCER RESEARCH FOUNDATION, AND ITS PROGENITOR ORGANIZATIONS, HAS BEEN COMMITTED TO FUNDING CUTTING EDGE RESEARCH THAT TRANSFORMS THE LUNG CANCER TREATMENT LANDSCAPE. WHEN WE FIRST OPENED OUR DOORS, OUR MISSION WAS SIMPLE: PROVIDE HOPE BY FUNDING THE BEST RESEARCH AND HELP BRING IT TO PEOPLE. WE HAVE BEEN WILDLY SUCCESSFUL. IN 16 YEARS, WE HAVE BECOME ONE OF THE LARGEST PRIVATE FUNDERS OF LUNG CANCER RESEARCH ENABLING EARLIER DETECTION, DEEPER UNDERSTANDING OF THE MECHANISMS THAT ALLOW LUNG CANCER TO FORM, AND NEW AND EXPANDED TREATMENT OPTIONS THAT HAVE SAVED MANY LIVES. SIMULTANEOUSLY, OUR SCIENTIFIC ADVISORY BOARD HAS BECOME ONE OF THE PREEMINENT BODIES IN THE LUNG CANCER RESEARCH COMMUNITY. FURTHERMORE, OUR INVESTMENT IN EARLY CAREER INVESTIGATORS CONTINUES TO ALLOW NEW TALENT TO THRIVE AND GROW IN THE SPACE AS IS DEMONSTRATED THROUGH FOLLOW-ON FUNDING MANY HAVE RECEIVED SINCE RECEIVING THEIR LCRF GRANT. TO DATE, LCRF HAS PROVIDED 394 RESEARCH GRANTS TOTALING NEARLY $39 MILLION, THE LARGEST AMOUNT PROVIDED BY A NON-GOVERNMENTAL ORGANIZATION DEDICATED TO FUNDING LUNG CANCER RESEARCH. THE SUPPORT WITHIN THE PATIENT COMMUNITY, RESEARCHERS, STRATEGIC PARTNERS, AND INDUSTRY PARTNERS IS KEY TO OUR PRESENT SUCCESSES AS WELL AS ACHIEVING OUR FUTURE VISION TO FIND AN EVENTUAL CURE FOR LUNG CANCER. DURING 2021 WE FUNDED ELEVEN (11) RESEARCH GRANTS; SIX (6) FOR TWO YEARS AT $150,000 EACH AND FIVE (5) FOR TWO YEARS AT $180,000 EACH. FOUR (4) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF PILOT GRANT PROGRAM WHICH FUNDS INNOVATIVE PROJECTS ACROSS THE FULL SPECTRUM OF BASIC, TRANSLATIONAL, CLINICAL, EPIDEMIOLOGICAL, HEALTH SERVICES, AND RESEARCH FOCUSED ON A MYRIAD OF TOPICS. THE PROJECTS FUNDED SPAN THREE COUNTRIES AND TOPICS INCLUDING: MANIPULATING THE FUNCTIONS OF T CELLS IN LUNG TUMOR DRAINING LYMPH NODES TARGETING LUNG LINEAGE PLASTICITY TO SUPPRESS OSIMERTINIB-INDUCED DRUG-TOLERANT PERSISTERS USING CD4+ T CELLS TO TARGET THE TUMOR MICROENVIRONMENT IN NON-SMALL CELL LUNG CANCER ELUCIDATING THE MOLECULAR MECHANISMS OF RADON-INDUCED LUNG CANCER THROUGH A NOVEL MOUSE MODELTWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF DISPARITIES IN LUNG CANCER PROGRAM WHICH FUNDS RESEARCH THAT ADDRESSES CERTAIN DISPARITIES THAT INCLUDE BUT ARE NOT LIMITED TO RACE AND GENDER-DEPENDENT DIFFERENCES; SOCIAL AND BIOLOGICAL RISK FACTORS; NEVER SMOKERS; EQUITY AND ACCESS TO HEALTH CARE; AND IMPACTS OF GEOGRAPHY, AGE, AND SOCIOECONOMIC STATUS ON OUTCOMES. THE PROJECTS FUNDED SPAN TWO COUNTRIES AND TOPICS INCLUDING: USING SOCIAL DETERMINANTS OF HEALTH TO PREDICT ADHERENCE OF LUNG CANCER SCREENING IN MINORITY HIGH-RISK SMOKERS INVESTIGATING THE ASSOCIATION BETWEEN AIR POLLUTION AND EGFR MUTANT NEVER-SMOKER LUNG CANCERIN PARTNERSHIP WITH ASTRAZENECA, LCRF AWARDED ANOTHER FIVE (5) RESEARCH GRANTS FOCUSED ON UNDERSTANDING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR AND IMMUNOTHERAPY RESISTANCE, TOTALING $900,000; GIVING EACH PROJECT $180,000 OVER A TWO-YEAR PERIOD. THE PROJECTS FUNDED INCLUDE THE FOLLOWING TOPICS: SUBCLONE CAPTURE SEQUENCING TO GUIDE COMBINATION THERAPY AND IMPROVE OSIMERTINIB RESPONSE TARGETING TUMOR-IMMUNE MICROENVIRONMENT TO IMPROVE DURVALUMAB EFFICACY IN SMALL CELL LUNG CANCER DISSECTING THE ROLE OF THE KEAP1 PATHWAY IN MEDIATING THERAPEUTIC SENSITIVITY IN EGFR-DRIVEN LUNG ADENOCARCINOMA INVESTIGATING THE ER ACETYL-COA TRANSPORTER AS A PUTATIVE METABOLIC DEPENDENCY OF MUTANT EGFR LUNG CANCER TARGETING YAP/TEAD BYPASS ACTIVATION IN OSIMERTINIB-INDUCED DRUG TOLERANT CELLS: A STRATEGY TO OVERCOMING TUMOR RECURRENCE AND THERAPEUTIC RESISTANCE IN EGFR-MUTANT NON-SMALL CELL LUNG CANCERSIN ADDITION TO THE DIRECT RESEARCH FUNDING PROVIDED THROUGH THE LCRF PILOT AND LCRF DISPARITIES GRANT TRACKS, THE FOUNDATION IS CURRENTLY ADMINISTRATING RESEARCH PARTNERSHIPS WITH PFIZER GLOBAL MEDICAL GRANTS AND THE LUNG CANCER MUTATION CONSORTIUM.THE LCRF AND PFIZER GLOBAL MEDICAL COLLABORATION TO FUND OVER $1 MILLION IN RESEARCH GRANTS THROUGH A COMPETITIVE RESEARCH GRANT PROGRAM WAS STARTED IN 2019 AND CONTINUED THROUGH 2021. THE RESEARCH GRANT OPPORTUNITY FOCUSED ON UNDERSTANDING WAYS TO IMPROVE CLINICAL PRACTICES FOR SIDE EFFECT MANAGEMENT FOR NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING TARGETED THERAPIES. THIS IS THE FIRST COLLABORATION OF ITS KIND IN LUNG CANCER AND COULD HAVE AN IMPACT ON PATIENT CARE. THE COLLABORATION BETWEEN LCRF AND PFIZER FUNDED FOUR (4) RESEARCH GRANTS COVERING TOPICS SUCH AS: REAL-TIME MONITORING AND MODELING OF SYMPTOMS AND ADVERSE EVENTS IN LUNG CANCER PATIENTS RECEIVING ORAL TARGETED THERAPIES FOR TUMORS WITH ONCOGENIC DRIVER MUTATIONS DEVELOPMENT AND IMPLEMENTATION OF 4R CARE SEQUENCES IN PATIENTS WITH NSCLC RECEIVING TARGETED THERAPIES IMPLEMENTATION STRATEGIES FOR MONITORING ADHERENCE IN REAL-TIME (ISMART) PROACTIVE MONITORING OF TREATMENT-RELATED ADVERSE EVENTS THROUGH A MOBILE APPLICATION IN NSCLC PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS: THE "EMPOWER ME" DIGITAL THERAPEUTIC STUDY.LCRF'S PARTNERSHIP WITH THE LUNG CANCER MUTATION CONSORTIUM (LCMC) DATES BACK TO 2011 COVERING THREE CLINICAL TRIALS. THE LCMC2 CLINICAL TRIAL ENROLLED 1,000 PATIENTS VIA A NETWORK OF FOURTEEN (14) NOTABLE DOMESTIC CLINICAL RESEARCH SITES. THE CLINICAL TRIAL STUDIED THE IMPACT OF SMOKING AND TP53 MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WITH TARGETABLE MUTATIONS. THE LCMC3 CLINICAL TRIAL BEGAN IN 2017 AND HAS ENROLLED 1,000 PATIENTS VIA A NETWORK OF FIVE (5) DOMESTIC CLINICAL RESEARCH SITES. LCMC3 IS DESIGNED AS A NEOADJUVANT AND ADJUVANT TRIAL OF IMMUNE CHECKPOINT BLOCKADE FOR STAGE IB-IIIA NON-SMALL CELL LUNG CANCER. FINAL REPORTING FROM THIS CLINICAL TRIAL SHOULD BE COMPLETED IN ALTER 2021 OR EARLY 2022. LAUNCHED IN LATE 2020, LCMC4 WILL BE A STUDY OF 1,000 PATIENTS VIA A NETWORK OF 25+ DOMESTIC CLINICAL RESEARCH SITES. THE GOAL OF THE CLINICAL TRIAL IS TO DETERMINE THE FEASIBILITY OF COMPREHENSIVE MOLECULAR PROFILING TO DETECT ACTIONABLE ONCOGENIC DRIVERS IN PATIENTS WITH SUSPECTED EARLY-STAGE LUNG CANCERS SCHEDULED TO UNDERGO BIOPSIES TO ESTABLISH THE DIAGNOSIS OF LUNG CANCER. IN 2021, OUR RESEARCH INVESTMENT WAS FUNDED WITHOUT THE NEED FOR DEFICIT SPENDING, AND WE ARE POISED TO GROW OUR RESEARCH INVESTMENT IN THE COMING YEARS. 1794780 PATIENT EDUCATION & OUTREACH:THE OVERALL GOAL OF THE LUNG CANCER RESEARCH FOUNDATION (LCRF)'S PATIENT EDUCATIONAL PORTFOLIO IS TO PROVIDE RELEVANT AND ACCURATE INFORMATION ON LUNG CANCER USING PATIENT-FRIENDLY LANGUAGE. OUR PATIENT EDUCATION MATERIALS ARE TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER, LEARN ABOUT TREATMENT OPTIONS, MAKE DECISIONS ABOUT CLINICAL TRIALS, AND UNDERSTAND THE IMPLICATIONS OF COMPREHENSIVE BIOMARKER TESTING. PATIENTS AND CAREGIVERS NEED INFORMATION AT ALL STEPS IN THE CONTINUUM OF CARE, FROM DIAGNOSIS THROUGH TREATMENT AND BEYOND. THE LUNG CANCER RESEARCH FOUNDATION HAS A PORTFOLIO OF EDUCATIONAL RESOURCES TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER AND LEARN ABOUT THEIR TREATMENT OPTIONS. HELPING PATIENTS TO UNDERSTAND NEW TREATMENTS AND THE HOPE OFFERED BY THESE TREATMENT ADVANCES ARE KEY OBJECTIVES OF OUR EDUCATIONAL MATERIALS. WE ALSO HAVE MATERIALS DESIGNED TO EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE PROBLEM AND WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE. IN 2021, LCRF DISTRIBUTED OVER 105,000 EDUCATIONAL MATERIALS TO LUNG CANCER PATIENTS, CAREGIVERS, ADVOCATES AND HEALTHCARE PROFESSIONALS ACROSS THE NATION IN BOTH PRINT AND DIGITAL FORMAT. OUR WEBSITE ALSO CONTAINS LINKS TO INFORMATION AND RESOURCES, WHICH RECEIVES ON AVERAGE OF MORE THAN 24,000 PAGEVIEWS ANNUALLY. OUR CONTINUED GOAL IS TO STEADILY INCREASE OUR MATERIALS DISTRIBUTED, PARTICULARLY WITH DIGITAL DOWNLOADS AS THERE HAS BEEN A SURGE IN DEMAND FOR READILY AVAILABLE INFORMATION. THE KEY OBJECTIVES OF THE PORTFOLIO ARE TO:- EMPOWER PATIENTS AND CAREGIVERS BY INCREASING THEIR KNOWLEDGE OF LUNG CANCER, TESTING AND TREATMENT OPTIONS - PROVIDE AN UP-TO-DATE AND CREDIBLE SOURCE OF INFORMATION ON TREATMENT OPTIONS AND EDUCATE PATIENTS ON WHAT TO EXPECT FROM TREATMENT AND WHAT WILL BE CRITICAL FOR BEST OUTCOMES. - PROVIDE TOOLS TO FACILITATE DISCUSSIONS BETWEEN PATIENTS AND HEALTHCARE PROVIDERS. - EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE PROBLEM AND WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE. - SHARE PROGRESS AND IMPACT OF RESEARCH (INCLUDING THAT WHICH IS FUNDED BY LCRF), AND EXPLAIN WHY FUNDING RESEARCH IS CRUCIAL FOR THE DEVELOPMENT OF NEW TREATMENTS FOR LUNG CANCER - ENSURE THAT THE MATERIALS ARE CULTURALLY APPLICABLE, APPROPRIATE LITERACY LEVELS, AND ACCESSIBLE FOR MARGINALIZED POPULATIONS. - ENGAGE PATIENTS AND CAREGIVERS IN DISCUSSION OF LUNG CANCER RESEARCH AND ITS INFLUENCE ON SCREENING, TREATMENT ADVANCES, AND HEALTH OUTCOMESTHE PATIENT EDUCATIONAL PROGRAMS REVIEW COMMITTEE (PEPRC) ASSISTS IN THE EVALUATION OF MATERIALS USED FOR LCRF'S PATIENT SUPPORT AND EDUCATIONAL PROGRAMS, AWARENESS CAMPAIGNS, AND OTHER PATIENT-FACING INITIATIVES. THE PEPRC CONSISTS OF MULTIDISCIPLINARY EXPERTS SUCH AS ONCOLOGISTS, RESEARCHERS, NURSES, SOCIAL WORKERS, AND LUNG CANCER PATIENTS/SURVIVORS. PEPRC ALSO AIDS IN SHAPING THE OVERALL STRATEGY BY LENDING THEIR RESPECTIVE EXPERTISE IN THE FIELD. THE PATIENT EDUCATIONAL PORTFOLIO IS ALSO CRAFTED WITH ASSISTANCE FROM THE FEEDBACK WE RECEIVE FROM OUR COMMUNITY. OUR MATERIALS ARE RATED ON AVERAGE A 4.6/5 ACCORDING TO THE FEEDBACK COLLECTED FROM INDIVIDUALS WHO DOWNLOAD OR ORDER OUR PRINT MATERIALS ON OUR WEBSITE. SAMPLE FEEDBACK INCLUDES:THANK YOU FOR PROVIDING FREE EDUCATIONAL RESOURCES. I AM A THORACIC NURSE NAVIGATOR AND PROVIDE THESE TO ALL OF MY LUNG CANCER PATIENTS. MY PATIENTS LIKE AND APPRECIATE THEM VERY MUCH.THANK YOU SO MUCH FOR PROVIDING INFORMATION TO PEOPLE TRYING TO NAVIGATE A LUNG CANCER DIAGNOSIS AND ALL THE STRESS RELATED TO THE ENTIRE PROCESS.MY MOTHER WAS RECENTLY DIAGNOSED WITH LUNG CANCER. VERY HEARTBREAKING AND A SURPRISE TO US ALL. HEARD NOTHING BUT GOOD REVIEWS ABOUT LCRF SO I LOOK FORWARD TO LEARNING ABOUT EVERYTHING AND I APPRECIATE WHAT YOU ALL DO.LUNG CANCER SUPPORT LINEOUR LUNG CANCER SUPPORT LINE IS A TOLL-FREE NUMBER (844)-835-4325, IS AVAILABLE TO ANYONE AFFECTED BY LUNG CANCER, PRIMARILY LUNG CANCER PATIENTS AND CAREGIVERS. THE SUPPORT LINE OPERATES MONDAY-FRIDAY 9AM-5PM ET AND IS EQUIPPED WITH EXTENSIVE AND UP-TO-DATE RESOURCE GUIDES FOR COMMON NEEDS AND SERVICES FOR LUNG CANCER PATIENTS SUCH AS FINANCIAL ASSISTANCE, TRANSPORTATION OR LODGING TO/FROM MEDICAL APPOINTMENTS, SUPPORT GROUPS, AND MUCH MORE. LUNG CANCER PATIENTS AND THEIR CAREGIVERS MAY CALL OR EMAIL THE PROGRAM AS OFTEN AS THEY WISH, AND THE SERVICE IS OFFERED FREE OF CHARGE. THE LUNG CANCER SUPPORT LINE HELPS FILL AN UNMET NEED BY PROVIDING PERSONALIZED, ONE-ON-ONE SUPPORT TO CALLERS WHO ARE FACING THE CHALLENGES OF LUNG CANCER. IN 2021, WE ASSISTED OVER 125 PATIENTS WITH LUNG CANCER AND THEIR CAREGIVERS THROUGH THE SUPPORT LINE, WITH AN ADDITIONAL 2,000 FOLLOW-UP ACTIONS FROM LCRF STAFF. OVER HALF OF CALLERS ARE NEWLY DIAGNOSED PATIENTS OR CAREGIVERS OF THOSE WHO ARE RECENTLY DIAGNOSED, PROVING THAT THE SUPPORT LINE PROVIDES A TIMELY SERVICE FOR THOSE SEEKING SUPPORT. THE REMAINDER OF SUPPORT LINE INQUIRIES COME IN FROM HEALTHCARE INSTITUTIONS OR COMMUNITY-BASED INSTITUTIONS LOOKING FOR RESOURCES FOR THEIR PATIENTS. OUR CONTINUED GOAL FOR THE SUPPORT LINE IS TO STRENGTHEN OUR COMMUNICATION WITH THOSE WHO ARE NEWLY DIAGNOSED AND ENGAGED IN OUR EDUCATIONAL PROGRAMS. WE ALSO HOPE TO INCREASE OUR SUPPORT LINE REACH BY 20% OVER THE NEXT YEAR VIA TARGETED OUTREACH AND PROMOTION OF OUR SERVICES. THROUGH THE SUPPORT LINE, WE PROVIDE:- A CENTRAL HUB FOR ACCESSING EMOTIONAL SUPPORT, PATIENT-SPECIFIC LOCAL AND NATIONAL RESOURCES- ACCURATE AND UP-TO-DATE EDUCATIONAL INFORMATION AND MATERIALS - OFFER PATIENTS AND CAREGIVERS OPPORTUNITIES TO CONNECT WITH OTHERS AND BECOME ENGAGED IN THE LCRF LUNG CANCER COMMUNITY#TOGETHERSEPARATELY SERIES LUNG CANCER AWARENESS, EDUCATION, AND ADVOCACY SUFFERS IN COMPARISON TO SOME OTHER DISEASES BECAUSE OF THE POOR PROGNOSIS AS WELL AS THE STIGMA PATIENTS MAY FACE GIVEN THE ASSOCIATION WITH SMOKING. ADVANCES IN TREATMENTS, HOWEVER, HAVE GIVEN PATIENTS AND CAREGIVERS NEW HOPE AND MANY ARE INTERESTED IN JOINING TOGETHER TO "MAKE A DIFFERENCE" IN THEIR OWN LUNG CANCER JOURNEY AS WELL AS IN THEIR BROADER COMMUNITY. AN IMPORTANT COMPONENT OF THE #TOGETHERSEPARATELY LIVE VIRTUAL SERIES IS THE ABILITY OF PATIENTS/SURVIVORS AND CAREGIVERS TO CONNECT AND RE-CONNECT WITH OTHERS WHO ARE LIVING WITH LUNG CANCER. WE WANT PATIENTS TO KNOW THAT THEY ARE NOT ALONE AND THAT WE ARE WORKING TO SUPPORT THE LUNG CANCER COMMUNITY. THIS LIVE MEETING FORMAT GIVES HOPE TO PARTICIPANTS THROUGH THE OPPORTUNITY TO MEET LUNG CANCER RESEARCHERS AND SPEAK TO RESEARCHERS ABOUT THEIR CONCERNS AND NEEDS. THESE NEEDS BECAME EVEN MORE EVIDENT WITH THE ONSET OF THE COVID-19 GLOBAL PANDEMIC IN MARCH 2020 THAT SHAPED THE WAY WE LIVE AND RECEIVE MEDICAL CARE. MANY LUNG CANCER PATIENTS EXPRESSED THEIR FEELINGS OF ISOLATION AND DESIRE FOR UPDATES ON CURRENT LUNG CANCER AND COVID-19 RELATED INFORMATION. THIS INSPIRED THE SERIES TO PROVIDE BOTH A CONNECTION WITH THE BROADER LUNG CANCER COMMUNITY AS WELL AS TO LEARN MORE ABOUT LUNG CANCER RELATED TOPICS. BY THE END OF EACH EVENT IN THE SERIES, NEW FRIENDSHIPS HAVE FORMED, INFORMATION HAS BEEN EXCHANGED, AND EVERYONEINCLUDING USLEAVES ENERGIZED AND INSPIRED. THE LEARNING OBJECTIVES OF THE LIVE VIRTUAL SERIES ARE: - LEARN THE FUNDAMENTALS OF LUNG CANCER AND TREATMENT OPTIONS - UNDERSTAND WHY FUNDING RESEARCH IS CRUCIAL FOR THE DEVELOPMENT OF NEW THERAPIES FOR PATIENTS - LEARN ABOUT PROGRAMS AND RESOURCES AVAILABLE TO THE LUNG CANCER COMMUNITY - CONNECT PATIENTS AND CAREGIVERS WITH LEADING PHYSICIANS IN THE FIELD OF LUNG CANCER - BUILD AND FOSTER COMMUNITY AMONG PATIENTS AND CAREGIVERS SINCE ITS INCEPTION IN MARCH 2020, WE HAD ALMOST 3,500 REGISTRANTS FOR AT LEAST ONE OF OUR #TOGETHERSEPARATELY EVENTS WITH AN AVERAGE ATTENDANCE RECORD OF OVER 100 INDIVIDUALS PER WEBINAR. MOST OF THE ATTENDEES IN THIS SERIES ARE LUNG CANCER PATIENTS, SURVIVORS, ADVOCATES, CAREGIVERS, AND COMMUNITY PROVIDERS. OUR GOAL IS TO CONTINUE THE SERIES AND PROVIDE 10-12 WEBINARS ANNUALLY ON A VARIETY OF TOPICS RELATED TO LIVING WITH LUNG CANCER. WE ALSO HAVE A COMPANION #TOGETHERSEPARELY SUPPORT GROUP ON FACEBOOK WHERE CONSTITUENTS CAN DEEPEN THEIR CONNECTIONS WITH EACH OTHER AND HAVE REGULAR INFORMATIONAL POSTS AND RESOURCES SHARED WITH THEM. CURRENTLY, THE FACEBOOK GROUP HAS 642 MEMBERS AND CONTINUES TO GROW EVERY MONTH. THIS ACTIVE GROUP HAS A STEADY ENGAGEMENT RATE BETWEEN 60-65% AND WE HOPE TO GROW THIS GROUP TO UP TO 800 MEMBERS BY THE END OF 2022. 4427994 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 17 0 1 19 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 15 15 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY AL AR FL GA KS KY ME MD MA MI MN HI NH NJ NC TN UT VA SC OR ND WA WV WI MS AK CA CO CT IL NM OH OK PA RI X X X MICHAEL NIEKAMP 2125881580 501 SEVENTH AVE SUITE 401 NEW YORK NY 10018 REINA HONTS CHAIRMAN 5.00 X X 0 0 0 BRENDON M STILES MD VICE CHAIR 3.00 X X 0 0 0 MARY ANN TIGHE VICE CHAIR 3.00 X X 0 0 0 AARON M TIGHE TREASURER 3.00 X X 0 0 0 KATERINA POLITI PHD DIRECTOR 1.00 X 0 0 0 JOAN H SCHILLER MD DIRECTOR 1.00 X 0 0 0 RAYMOND E CHALME DIRECTOR 1.00 X 0 0 0 BRUCE DUNBAR DIRECTOR 1.00 X 0 0 0 PETER FRY DIRECTOR 1.00 X 0 0 0 JILL FURMAN DIRECTOR 1.00 X 0 0 0 SCOTT MORRIS DIRECTOR 1.00 X 0 0 0 RONALD D SERNAU DIRECTOR 1.00 X 0 0 0 SCOTT L STACKMAN DIRECTOR 1.00 X 0 0 0 ROSE ANN WEINSTEIN DIRECTOR 1.00 X 0 0 0 COLLEN CONNOR-ZIEGLER DIRECTOR 1.00 X 0 0 0 DENNIS CHILLEMI EXECUTIVE DIRECTOR 40.00 X 240000 0 8630 MICHAEL NIEKAMP VP, FINANCE & ADMINISTRATION 40.00 X 171976 0 32317 AUBREY RHODES SENIOR VP, STRATEGY 40.00 X 146865 0 17306 SAMUEL ROGERS VP, DEVELOPMENT 40.00 X 131987 0 36923 SHEILA SULLIVAN SR. DIRECTOR, MARKETING & COMMUNICATIONS 40.00 X 124308 0 48579 TONEL RODGERS ASSOCIATE DIRECTOR, FINANCE & ADMINSTRATION 40.00 X 108211 0 18941 923347 0 162696 7 0 1 0 CONRAD & ASSOCIATES LLC ELEVEN TIME SQUARE NEW YORK NY 10036 AME CONSULTANT 355000 PROSKAUER ROSE LLP ELEVEN TIME SQUARE NEW YORK NY 10036 ATTORNEY 154081 PUSH DIGITAL LLC 342 EAST BAY ST CHARLESTON SC 29401 MANAGERIAL CONSULTANT 127500 3 1688000 390832 4265527 6344359 1402 1402 0 1688000 249163 -249163 -249163 RETURNED GRANTS 900099 51328 51328 MISCELLANEOUS REVENUE 900099 6326 6326 57654 6154252 57654 0 -247761 1469919 1469919 330000 330000 240000 180000 48000 12000 1368572 966710 134683 267179 57008 40640 6474 9894 269223 191922 30576 46725 119983 81927 15053 23003 149083 147588 591 904 33304 16653 8326 8325 73650 73650 107071 75813 10678 20580 73210 37987 2463 32760 181979 127966 15603 38410 93059 65437 7980 19642 11901 11306 595 1219 1219 57464 40408 4927 12129 24402 17159 2092 5151 PUBLIC RELATIONS 410542 410542 PROGRAM MATERIALS 214798 214798 BAD DEBTS 37969 37969 STATE FILING FEES 13996 13996 2136 2136 5340488 4427994 290177 622317 44501 17800 0 26701 132232 199450 3778569 4773589 551477 595226 28801 143915 203585 181170 79879 22415 11000 3500 4581958 5738095 330585 341683 1164139 1527047 393000 361367 1887724 2230097 X 2607323 2209943 86911 1298055 2694234 3507998 4581958 5738095 813764 0 X X 0 1 X 1 0 X 4561443 6296669 5916763 5465693 6344359 28584927 4387 102325 55965 162677 4565830 6398994 5972728 5465693 6344359 28747604 443681 268750 423102 309650 229555 1674738 0 443681 268750 423102 309650 229555 1674738 27072866 41046 7994 3178 1357 1402 54977 41046 7994 3178 1357 1402 54977 26619 25949 9182 34702 57654 154106 4633495 6432937 5985088 5501752 6403415 28956687 0.93490 0.92450 0.00190 0.00210 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: RETURNED GRANTS - 2017 AMOUNT: $ 26,619. 2018 AMOUNT: $ 614. 2019 AMOUNT: $ 7,125. 2020 AMOUNT: $ 33,306. 2021 AMOUNT: $ 51,328. FEE FOR SERVICE - 2018 AMOUNT: $ 25,335. 2019 AMOUNT: $ 2,057. 2020 AMOUNT: $ 1,396. 2021 AMOUNT: $ 6,326. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 203585 181170 22415 22415 X 6786870 757596 757596 6029274 124978 124978 6154252 5973106 757596 757596 5215510 124978 124978 5340488 PART X, LINE 2: THE FOUNDATION IS ORGANIZED AS A NEW YORK STATE NONPROFIT CORPORATION AND HAS BEEN RECOGNIZED BY THE INTERNAL REVENUE SERVICE ("IRS") AS EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE ("IRC") SECTION 501(A) AS ORGANIZATIONS DESCRIBED IN IRC SECTION 501(C)(3). THE FOUNDATION IS ANNUALLY REQUIRED TO FILE A RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX (FORM 990-T) WITH THE IRS. IN ADDITION, THE ENTITY IS SUBJECT TO INCOME TAX ON NET INCOME THAT IS DERIVED FROM BUSINESS ACTIVITIES THAT ARE UNRELATED TO ITS EXEMPT PURPOSES. THE FOUNDATION HAS DETERMINED THAT IT IS SUBJECT TO UNRELATED BUSINESS INCOME TAX. THE FOUNDATION RECOGNIZES AND MEASURES ITS UNRECOGNIZED TAX BENEFITS IN ACCORDANCE WITH FASB ASC 740, INCOME TAXES. UNDER THAT GUIDANCE, THE FOUNDATION ASSESSES THE LIKELIHOOD, BASED ON THEIR TECHNICAL MERIT, THAT TAX POSITIONS WILL BE SUSTAINED UPON EXAMINATION BASED ON THE FACTS, CIRCUMSTANCES AND INFORMATION AVAILABLE AT THE END OF EACH PERIOD. THE MEASUREMENT OF UNRECOGNIZED TAX BENEFITS IS ADJUSTED WHEN NEW INFORMATION IS AVAILABLE, OR WHEN AN EVENT OCCURS THAT REQUIRES A CHANGE. MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND BELIEVES THAT THE FOUNDATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE ADJUSTMENTS TO THE FINANCIAL STATEMENTS. PART XI, LINE 4B - OTHER ADJUSTMENTS: RETURNED GRANTS INCLUDED WITH GRANTS EXPENSE 51,328. PROFESSIONAL FUNDRAISING FEES 73,650. PART XII, LINE 4B - OTHER ADJUSTMENTS: GROSS UP OF GRANTS EXPENSE 51,328. PROFESSIONAL FUNDRAISING FEES 73,650. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS RESEARCH GRANT 330000 0 0 0 0 0 0 330000 0 330000 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 150000 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT 180000 0 2 0 0 0 0 0 0 PART I, LINE 2: APPLICATIONS TO LCRF'S SCIENTIFIC GRANT PROGRAM ARE REVIEWED VIA A THREE-PART PROCESS. THEY ARE FIRST SCREENED BY LCRF STAFF TO ENSURE COMPLETENESS AND COMPLIANCE WITH ELIGIBILITY CRITERIA, BUDGET, AND OTHER SUBMISSION REQUIREMENTS. THE APPLICATIONS ARE NEXT SCREENED FOR SCIENTIFIC RATIONALE, CREATIVITY, APPROPRIATENESS OF TIMELINES AND BUDGET, INSTITUTIONAL LETTERS OF SUPPORT AND IMPACT ON THE FIELD OF LUNG CANCER RESEARCH BY THE LCRF SCIENTIFIC ADVISORY BOARD (SAB).NEXT, A SET OF SEMI-FINALISTS ARE INDEPENDENTLY AND COMPREHENSIVELY REVIEWED BY SUBCOMMITTEES OF THREE EXPERTS FROM THE SAB AND SCORED BY STANDARD NIH/NCI CRITERIA. UPON COMPLETION OF THE REVIEW PROCESS, APPLICATIONS ARE RANKED IN ORDER FROM HIGHEST TO LOWEST-SCORING, AND PROPOSALS SELECTED TO BE CONSIDERED FOR FUNDING ARE CHOSEN BASED STRICTLY ON THE APPLICATION SCORES NO EXTERNAL REVIEW IS ALLOWED. PART III ACCOUNTING METHOD: X X 1 ON THE LOT EVENTS DBA OP3 1150 WEST 48TH STREET LOS ANGELES CA 90037 FUNDRAISING & EVENT MANAGEMENT 0 894082 73650 820432 894082 73650 820432 NY AL AR FL GA KS KY ME MD MA MI MN HI NH NJ NC TN UT VA SC OR ND WA WV WI MS AK CA CO CT IL NM OH PA RI ELLIOTS LEGACY 530914 530914 33748 24236 1000 33195 VIRTUAL WALK 330561 330561 12234 7 826525 826525 144750 1688000 1688000 33748 24236 1000 190179 249163 -249163 1 CITY OF HOPE 1500 E DUARTE RD DUARTE CA 91010 953435919 501(C)(3) 150000 0 RESEARCH UNIVERSITY OF UTAH 201 PRESIDENTS CIRCLE SALT LAKE CITY UT 84112 876000525 501(C)(3) 150000 0 RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 150000 0 RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE L LEVY PL NEWYORK NY 10029 136171197 501(C)(3) 150000 0 RESEARCH YALE UNIVERSITY 2 WHITNEY AVENUE 6TH FL NEW HAVEN CT 06510 060646973 501(C)(3) 149919 0 RESEARCH UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE SAN ANTONIO TX 782293900 741586031 501(C)(3) 180000 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 100656007 131924236 501(C)(3) 180000 0 RESEARCH DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02115 042263040 501(C)(3) 180000 0 RESEARCH DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02115 042263040 501(C)(3) 180000 0 RESEARCH 9 PART I, LINE 2: APPLICATIONS TO LCRF'S SCIENTIFIC GRANT PROGRAM ARE REVIEWED VIA A THREE-PART PROCESS. THEY ARE FIRST SCREENED BY LCRF STAFF TO ENSURE COMPLETENESS AND COMPLIANCE WITH ELIGIBILITY CRITERIA, BUDGET, AND OTHER SUBMISSION REQUIREMENTS. THE APPLICATIONS ARE NEXT SCREENED FOR SCIENTIFIC RATIONALE, CREATIVITY, APPROPRIATENESS OF TIMELINES AND BUDGET, INSTITUTIONAL LETTERS OF SUPPORT AND IMPACT ON THE FIELD OF LUNG CANCER RESEARCH BY THE LCRF SCIENTIFIC ADVISORY BOARD (SAB).NEXT, A SET OF SEMI-FINALISTS ARE INDEPENDENTLY AND COMPREHENSIVELY REVIEWED BY SUBCOMMITTEES OF THREE EXPERTS FROM THE SAB AND SCORED BY STANDARD NIH/NCI CRITERIA. UPON COMPLETION OF THE REVIEW PROCESS, APPLICATIONS ARE RANKED IN ORDER FROM HIGHEST TO LOWEST-SCORING, AND PROPOSALS SELECTED TO BE CONSIDERED FOR FUNDING ARE CHOSEN BASED STRICTLY ON THE APPLICATION SCORES NO EXTERNAL REVIEW IS ALLOWED. X 0 0 0 0 0 0 0 0 0 DENNIS CHILLEMI EXECUTIVE DIRECTOR 240000 0 0 0 0 0 8123 0 507 0 248630 0 0 0 MICHAEL NIEKAMP VP, FINANCE & ADMINISTRATION 171976 0 0 0 0 0 7002 0 25315 0 204293 0 0 0 SHEILA SULLIVAN SR. DIRECTOR, MARKETING & COMMUNICAT 124308 0 0 0 0 0 5205 0 43374 0 172887 0 0 0 SAMUEL ROGERS VP, DEVELOPMENT 131987 0 0 0 0 0 4068 0 32855 0 168910 0 0 0 AUBREY RHODES SENIOR VP, STRATEGY 146865 0 0 0 0 0 5951 0 11355 0 164171 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 MARY ANN TIGHE AND AARON M. TIGHE - FAMILY RELATIONSHIP MARY ANN TIGHE AND RAYMOND E. CHALME - BUSINESS RELATIONSHIP MARY ANN TIGHE AND RONALD D. SERNEAU - BUSINESS RELATIONSHIP FORM 990, PART VI, SECTION B, LINE 11B THE INITIAL DRAFT OF THE IRS FORM 990 IS REVIEWED BY MANAGEMENT FOR COMPLETENESS AND ACCURACY. ONCE MANAGEMENTS REVIEW IS COMPLETE, THE DRAFT IS SENT TO EACH MEMBER OF THE BOARD OF DIRECTORS FOR REVIEW, COMMENT, AND APPROVAL. IF ANY CHANGES ARE MADE, THE REVISED DRAFT IS RESENT TO THE BOARD FOR REVIEW AGAIN. UPON FINAL APPROVAL, THE RETURN IS FILED WITH THE INTERNAL REVENUE SERVICE ELECTRONICALLY. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS THE CONFLICT OF INTEREST POLICY ANNUALLY, AND ASKS ALL BOARD MEMBERS AND EMPLOYEES TO DISCLOSE ANY CONFLICTS OR POTENTIAL CONFLICTS. IN ADDITION, ALL CONTRACTS ARE REVIEWED FOR KNOWN OR POTENTIAL CONFLICTS BY THE EXECUTIVE DIRECTOR, SR. DIRECTOR FINANCE & ADMINISTRATION AND THE EXECUTIVE COMMITTEE ON AN ON-GOING BASIS. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE OF THE BOARD LOOKS AT COMPENSATION SURVEYS AND ALSO COMPARES SALARIES IN SIMILAR ORGANIZATIONS TO DETERMINE THE REASONABLENESS OF SALARIES FOR KEY EMPLOYEES. THE EXECUTIVE COMMITTEE ALSO CONSIDERS OTHER PERFORMANCE-BASED CRITERIA WHICH INCLUDES A WRITTEN PERFORMANCE APPRAISAL OF THE EXECUTIVE DIRECTOR. FORM 990, PART VI, SECTION C, LINE 18 THE IRS FORM 990 IS AVAILABLE ON THE ORGANIZATIONS WEBSITE. ALL OTHER DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON RECEIPT OF A WRITTEN REQUEST. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS, CONFLICT OF INTEREST POLICY, AND DONOR PRIVACY POLICY ARE AVAILABLE ON THE ORGANIZATIONS WEBSITE OR BY WRITTEN REQUEST. FORM 990, PART XII, LINE 2C THE ORGANIZATION DID NOT CHANGE ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.